ERBB2 and non-small cell lung carcinoma: Interestingly, data from another single-arm prospective study evaluating pyrotinib in 27 advanced HER2-amplified NSCLC patients revealed good efficacy and safety with an ORR of 22.2%, a median PFS of 6.3 months, and a median OS of 12.5 months.